Shanghai plans to test the price of medical insurance drugs purchased in volume

Source: new express 2013-08-13 recently, Shanghai bidding Office disclosed the implementation plan of pilot "volume purchase" of medical insurance drugs in Shanghai at the pharmaceutical seminar According to the implementation plan of trial "on quantity purchase" of medical insurance drugs in Shanghai, there are four kinds of nucleoside reverse transcriptase inhibitors for hepatitis B in trial quantity purchase at the initial stage: Lamivudine, telbivudine, entecavir and adefovir dipivoxil The other three varieties are docetaxel injection (involving 19 enterprises), tegio oral regular release (involving 3 enterprises) and oxaliplatin injection (involving 17 enterprises) It is said that the plan was opposed by local pharmaceutical companies According to people in the pharmaceutical industry, what the local pharmaceutical companies oppose is not "purchasing with quantity", but killing the price fiercely It is reported that the above schemes are obviously beneficial to foreign-funded enterprises in terms of quality stratification, bidding rules and the number of bid winning enterprises, while domestic enterprises can only win the bid at a low price, which is negative for large and medium-sized brand enterprises, so it is a probability event that they will be strongly resisted by large and medium-sized domestic brand enterprises Enterprise representative: high quality generic drugs suffer unfair competition, so-called "purchasing with quantity", that is, medical institutions carry out "group buying" and jointly sign purchase and sale contracts with pharmaceutical factories, so as to minimize the space for false high prices of drugs This is that the payers of medical insurance directly participate in the bidding of medical insurance drugs Its purpose is to make profits for the people on the basis of not increasing the burden of medical insurance funds, which is worthy of affirmation However, many people in the pharmaceutical industry believe that the above schemes are more favorable to foreign pharmaceutical enterprises in terms of bidding varieties and purchase prices According to the disclosure, the plan points out that the procurement of the original research drugs is carried out through a single source procurement, and those with drug price reduction greater than 10% are included in the "volume procurement"; those with drug price reduction less than 10% are included in the "volume procurement"; the two varieties with the largest reduction are selected to implement the "volume procurement", and other varieties remain the same as the original procurement However, the procurement of generic drugs can be carried out through competitive bidding On the premise of quality assurance, those with low price win the bid and those who fail to win the bid will not be allowed to purchase generic drugs This means that 10% or even less than 10% of the price reduction of original research drugs can be included in the volume procurement, while the two with the lowest price frame are selected for generic drugs, even if 50% of the price reduction may not be included in the shortlist "The bidding drugs are directly divided into two quality levels - original research drugs and generic drugs, and different ways of volume purchase are adopted for the original research drugs and generic drugs." At the seminar on "purchasing with volume" recently convened by the China Council for the promotion of drugs, a group of representatives of member enterprises and relevant experts said, "this provision undoubtedly causes unfair competition between the original research drugs and high-quality generic drugs." Drug promotion association: it is understood that the bidding varieties and purchase prices need to be adjusted Even if the price of the original research drug is reduced by 10%, it is much higher than the price of generic drugs Moreover, generic drugs are divided into high-quality generic drugs and generic generic drugs Representatives of the China Council for the promotion of drugs suggested that the pilot varieties should be divided into two quality levels for competition and procurement First, high-quality drugs, including patent drugs, original research drugs, imported generic drugs approved by mainstream countries and regions such as Europe, the United States and Japan and registered in China, domestic generic drugs first passing the quality certification in Europe and the United States, domestic generic drugs passing the quality consistency evaluation organized by the State Food and Drug Administration and the new version of GMP Drugs produced by certified enterprises; second, generic drugs of general quality, i.e according to the current drug standards in China As for the purchase price, the above representatives suggested that for the purchase price of the original research drugs, the benchmark price should be determined by referring to the prices of the same varieties in the surrounding regions and countries of mainland China; for the generic drugs, a reasonable median price for bidding should be determined according to the market situation nationwide Some insiders said that the principle of further improving the concentration of the pharmaceutical production industry has not changed, the principle of "only low price procurement" has not changed, the principle of government leading price has not changed, and the fight has already begun, but this plan is more cruel and directly announced the direct exit of some small and medium-sized players Mi Aiguo, a senior policy researcher, believes that to link is not only to measure the price, but also to "measure the price" and to stipulate the responsibilities and obligations of the buyer and the seller in the contract